(Q54362636)

English

Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol (English)

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

phase II clinical trial

0 references

endometrial carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Alessandro D Santin

1

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

language of work or name

0 references

publication date

20 February 2010

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

Gynecologic Oncology

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

118

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

1

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

95-6; author reply 96-7

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

Use of trastuzumab in the treatment of metastatic endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.043

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.01.043

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/20172595

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54362636&oldid=1774230865"